EP1180937A4 - Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine - Google Patents

Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine

Info

Publication number
EP1180937A4
EP1180937A4 EP00931911A EP00931911A EP1180937A4 EP 1180937 A4 EP1180937 A4 EP 1180937A4 EP 00931911 A EP00931911 A EP 00931911A EP 00931911 A EP00931911 A EP 00931911A EP 1180937 A4 EP1180937 A4 EP 1180937A4
Authority
EP
European Patent Office
Prior art keywords
vancomycin
strains
enterococcus faecium
patients infected
resistant enterococcus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931911A
Other languages
German (de)
English (en)
Other versions
EP1180937A1 (fr
Inventor
Carl R Merril
Richard M Carlton
Sankar Adhya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Exponential Biotherapies Inc
Original Assignee
National Institutes of Health NIH
Exponential Biotherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, Exponential Biotherapies Inc filed Critical National Institutes of Health NIH
Publication of EP1180937A1 publication Critical patent/EP1180937A1/fr
Publication of EP1180937A4 publication Critical patent/EP1180937A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP00931911A 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine Withdrawn EP1180937A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13405599P 1999-05-13 1999-05-13
US134055P 1999-05-13
PCT/US2000/006718 WO2000069269A1 (fr) 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine

Publications (2)

Publication Number Publication Date
EP1180937A1 EP1180937A1 (fr) 2002-02-27
EP1180937A4 true EP1180937A4 (fr) 2004-08-04

Family

ID=22461568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931911A Withdrawn EP1180937A4 (fr) 1999-05-13 2000-05-12 Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine

Country Status (5)

Country Link
EP (1) EP1180937A4 (fr)
JP (1) JP2002543816A (fr)
AU (1) AU4971900A (fr)
CA (1) CA2373486A1 (fr)
WO (1) WO2000069269A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250143A2 (fr) 2000-01-11 2002-10-23 Intralytix Inc. Reduction de la colonisation bacterienne par administration de compositions bacteriophages
US6759229B2 (en) 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
WO2004052274A2 (fr) 2002-12-09 2004-06-24 Phage Biopharm Llc Production de compositions bacteriophages destinees a etre utilisees dans la therapie phagique
DE10342071B4 (de) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
KR100958139B1 (ko) * 2008-03-31 2010-05-18 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패칼리스 특이적 사멸능을 갖는 신규한박테리오파지
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
KR100988771B1 (ko) * 2008-09-29 2010-10-20 주식회사 인트론바이오테크놀로지 엔테로코쿠스 및 스트렙토코쿠스 특이적 사멸능을 갖는 신규한 리신 단백질
RU2580248C9 (ru) * 2009-02-06 2018-01-17 Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са Бактериофаг, обладащий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения
WO2017177196A1 (fr) 2016-04-08 2017-10-12 The Trustees Of Princeton University Nouvelles compositions antimicrobiennes et méthodes d'utilisation
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
KR101822812B1 (ko) * 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
KR102203679B1 (ko) * 2018-12-26 2021-01-15 주식회사 옵티팜 신규한 엔테로코커스 패시움 균 특이 박테리오파지 ef44 및 이를 포함하는 항균 조성물
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
IL309276A (en) * 2021-06-15 2024-02-01 Ferring Bv Bacteriophages against vancomycin-resistant enterococci
WO2024003301A1 (fr) 2022-06-29 2024-01-04 Snipr Biome Aps Ciblage de cellules d'e. coli

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766892A (en) * 1994-04-05 1998-06-16 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766892A (en) * 1994-04-05 1998-06-16 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALISKY J ET AL: "BACTERIOPHAGE SHOW PROMISE AS ANTIMICROBIAL AGENTS", JOURNAL OF INFECTION, ACADEMIC PRESS, LONDON, GB, vol. 36, 1998, pages 5 - 15, XP000993238, ISSN: 0163-4453 *
See also references of WO0069269A1 *

Also Published As

Publication number Publication date
JP2002543816A (ja) 2002-12-24
AU4971900A (en) 2000-12-05
WO2000069269A1 (fr) 2000-11-23
CA2373486A1 (fr) 2000-11-23
WO2000069269A9 (fr) 2002-02-21
EP1180937A1 (fr) 2002-02-27

Similar Documents

Publication Publication Date Title
EP1180937A4 (fr) Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine
EE04344B1 (et) Telmisartaani polümorfid, meetodid nende valmistamiseks ja nende kasutamine ravimi valmistamiseks
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL337867A1 (en) Oral preparation of controllable opioidic analgesic agent release
AU6089200A (en) Rapid immediate release oral dosage form
EE04589B1 (et) Vähivastaste ühendite valmistamise protsessid ja vaheühendid
HRP20050278A2 (en) Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
PL365080A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU1167602A (en) Methods of therapy for hiv infection
AU2001295512A1 (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
PL360885A1 (en) 10-aryl-11h-benzo [b]fluorene derivatives and analogs for medicinal use
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
IT1282586B1 (it) Composizioni farmaceutiche per il trattamento biologico delle infezioni dovute a ceppi di enterococcus faecium resistenti agli
PT1165136E (pt) Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular
HUP0201405A3 (en) Pharmaceutical composition for therapeutic use of melatonin
AU2126100A (en) Polyoxofluorometallates and use thereof as catalysts for the epoxidation of alkenes
PL352528A1 (en) Novel xanthone compounds, their preparation and use as medicament
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
GB9925899D0 (en) Patient monitor
HUP0201239A2 (en) Disposable safety syringe
ITMI991950A0 (it) Procedimento per la sintesi del ritomavir
ITMI992023A0 (it) Procedimento per la preparazione e purificazione del tramadol
GB9926501D0 (en) Wheelchair push ring gripping attachment
GB2348363B (en) Improvements to elevator chairs for the handicapped and invalids
TW543442U (en) Structure of brake for wheelchair

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040623

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201